Neuren Lifts Income Guidance as DAYBUE Sales Rise and German Launch Triggers Milestone
NEU: $23.24 +17.49% · MC: $2.9B
Neuren Pharmaceuticals raised its annual trofinetide income guidance to US$91 million–US$93 million from US$53 million–US$56 million, including a US$35 million milestone earned from the drug’s German launch. Partner Acadia reported quarterly DAYBUE sales rose 39% from a year earlier to US$140 million, while Neuren’s royalties rose 51% to US$16 million. Acadia also raised its annual global sales guidance and plans a Japanese regulatory filing next year, with a potential launch the following year subject to approval.

Comments